Who paid for the study matters, even when the science is real

Key takeaways

• A 2017 Cochrane review of 75 papers found that drug and device studies paid for by industry more often reported results and conclusions that favored the sponsor.
• The tilt rarely comes from faked data; it comes from which questions get asked, which results get published and how the findings are described.
• Supplement makers face the same pull: in 2024 a federal court barred the maker of Prevagen from eight memory claims after a jury found its claims unsupported.
• Company funding doesn’t make a study wrong, and a well-run trial can be good evidence, especially when it was registered in advance and repeated by an independent team.
• You can learn who paid, whether the trial was registered and whether the sponsor shaped the paper in about five minutes with the routine below.

In 1965, a sugar trade group paid two Harvard nutrition scientists $6,500 to review the research on diet and heart disease. That was about $48,000 in 2016 dollars².

The review ran in the New England Journal of Medicine in 1967. It blamed dietary fat and cholesterol and played down the evidence against sugar¹².

Decades later, a researcher at the University of California, San Francisco, dug up the group’s internal letters². They showed that the Sugar Research Foundation set the review’s goal, suggested studies to include and read drafts. Readers were never told¹.

If you already distrust research paid for by drug companies, that story probably confirms your instincts. It should. But the same lens applies to every company that sells a product with a study attached, including makers of supplements, superfoods and wellness gadgets.

This article explains how funding shapes research, why the effect usually isn’t outright fraud, and how to check who paid for a study in about five minutes. The goal is to know how much weight each one deserves.

Sponsored research is normal, but the real question is who controlled it

Sponsored research means someone with a stake in the answer paid for some or all of the work. That might be a drug maker, a food company, a trade group or a supplier that sells an herbal extract.

The money takes many forms. It can be a grant, free product, a consulting fee paid to the scientist, or a full contract in which the company designs the study and owns the data.

How much control the sponsor had matters more than the check itself. The International Committee of Medical Journal Editors (ICMJE), whose rules many leading journals follow, says every paper should name its sponsors and state what role they played in design, data collection, analysis, writing and the decision to publish¹¹. It also tells authors to avoid deals that limit their access to the data or their freedom to publish¹¹.

A sponsor that sends money and steps back is very different from one that writes the plan, keeps the data and drafts the paper. The disclosure statement is where you find out which kind you’re dealing with.

Company-funded studies favor the company, and the biggest review says so

In 2017, a team led by researcher Andreas Lundh published a Cochrane review. Cochrane reviews are careful summaries that pool every good study on a question. This one gathered 75 papers that compared drug and device research funded by industry with research funded by others³.

Industry-funded studies were about 27% more likely to report favorable results. They were about 34% more likely to reach favorable conclusions³.

Here is the surprising part. The industry studies were not sloppier by the usual quality checks. Random assignment, follow-up and selective reporting looked about the same, and industry studies were more often well blinded, meaning participants and researchers didn’t know who got what³. The authors concluded that the bias comes from something standard quality checklists don’t catch³.

Food research shows a similar pattern. A 2007 analysis in the journal PLoS Medicine examined 206 articles on soft drinks, juice and milk published from 1999 to 2003⁴. Among experiments paid for entirely by industry, none reached a conclusion unfavorable to the sponsor. Among experiments with no industry money, 37% did⁴.

Overall, full industry funding made a favorable conclusion roughly four to eight times as likely⁴. Nearly half of the articles didn’t state their funding at all⁴.

The concern has reached Washington. In May 2025, the White House’s Make America Healthy Again Commission cited those same beverage figures in arguing that industry money may tilt nutrition science toward sponsors’ products¹⁵.

The tilt rarely looks like fraud, but it hides in five ordinary choices

Most sponsored studies don’t invent data. Bias slips in through decisions that each look reasonable on their own. Watch for these five.

1. The question. The sponsor picks what gets studied and what it’s compared with. The sugar group set the goal of the review it paid for¹. A company can also choose an easy comparison, such as testing its product against nothing instead of against the best option already available.

2. The design. In 2016, the Associated Press reported on a paper funded by a candy trade group that found children who eat candy tend to weigh less than those who don’t⁵. It used surveys asking people to recall one day of eating, a design that can’t show cause and effect. The authors said so. The industry’s news release left that caveat out⁵.

3. What gets published. The same AP report described a 2011 Quaker Oats trial with 48 people. It compared the company’s oatmeal and one of its cold cereals with Honey Nut Cheerios. The oatmeal proved more filling, the cereal results were mixed, and only the oatmeal results were published⁵.

4. Moving the goalposts. The Federal Trade Commission (FTC) warns that sifting through data after a trial ends, hunting for any subgroup that improved, is a sign of data mining and generally doesn’t count as proof⁶. Its guidance even describes a hypothetical juice maker that paid for two trials, changed the main outcome after seeing the first, and relied only on the smaller, positive one⁶.

5. The spin. A study can be sound while its summary oversells it. The Cochrane team found hints that industry papers’ conclusions matched their own results less often, though only a handful of studies measured this³. Always check whether the headline claim comes from the main result or a side result.

Supplement makers have used the same playbook

Prevagen is a memory supplement built on a protein that, according to the company, was first found in a jellyfish. Its maker, Quincy Bioscience, leaned mainly on its own trial of 218 adults, called the Madison Memory Study⁷⁸.

According to a 2017 complaint from the FTC and New York State, Prevagen did no better than a placebo on any of nine memory and thinking tasks⁷. The complaint says researchers then ran more than 30 analyses of smaller subgroups and found a few isolated wins. It also says ads charted one task and left out a time point when Prevagen scored slightly worse than placebo⁷.

Those were allegations. In 2024, a federal jury found that Quincy had not backed any of its Prevagen claims with reliable science⁸. The claims at issue included that the product was “clinically shown” to help memory⁸. In December 2024, Judge Louis Stanton barred the company from using eight challenged statements anywhere it sells Prevagen⁹.

POM Wonderful, the pomegranate juice company, shows a different side of the problem. By 2010, POM and its owners had spent more than $35 million funding over 100 studies at 44 institutions¹⁰. That is serious research money.

Even so, a federal appeals court agreed in 2015 that POM’s ads went beyond what the studies showed¹⁰. In one study of 53 men with erectile dysfunction, the juice failed on the standard, validated measure. A one-question measure came close but still fell short. POM promoted the near miss¹⁰.

The court upheld the FTC’s demand for at least one randomized controlled trial, a study where people are assigned by chance to the product or a comparison, before a company claims its product treats a disease¹⁰. The lesson: a company can fund a lot of real research and still oversell it. A big pile of studies is not the same as strong proof.

“Clinically studied” often means a cousin of your product was studied

Many supplement trials test a trademarked extract made by an ingredient supplier. The NIH Office of Dietary Supplements’ fact sheet on ashwagandha lists trials using branded extracts such as KSM-66, Sensoril and Shoden¹³. It notes that the studies used different preparations at different doses, which makes it hard to say which product or amount works¹³.

That matters at the store. A bottle may contain the exact extract that was tested, or a cheaper version of the same plant. The FTC’s guidance says that if a product uses a different extraction method with a different chemical makeup, studies of another extract may not apply⁶.

So when a label says “clinically studied,” ask three things. Was the tested extract the same one in this bottle? Was the dose the same? And who paid for that study?

A companion article on spotting thin evidence walks through the ingredient-versus-product gap in more detail.

What the evidence says about sponsored research

Claim	Evidence rating	What’s behind it
Industry-funded drug and device studies more often report favorable results and conclusions	Strong evidence	Cochrane review of 75 papers, 20173
Industry-funded food and beverage studies more often favor the sponsor	Promising but early	A consistent pattern, but from fewer and smaller analyses, such as the 206-article beverage study4
Industry-funded supplement trials tilt toward the sponsor	Not enough evidence	Documented cases exist710, but the large reviews cited here covered drugs, devices and beverages
The tilt comes from obviously sloppy methods	Evidence says no	Industry studies scored the same or better on standard quality checks3
Any company-funded study is worthless	Evidence says no	Funding predicts a modest tilt, not a wrong answer; the FTC gives weight to well-run, registered, repeated trials36

A five-minute funding check

You don’t need a science degree to do this. You need the study itself and a few minutes.

1. Find the actual study, not the ad (1 minute). Ask the seller for the full citation, then search the title online. A press release or a chart on a website is not the study.
2. Read the funding and conflict statements (1 minute). They’re usually near the end of the paper. Note who paid, whether any author works or consults for the company, and whether the sponsor helped design, analyze or write the study. A missing statement is itself a warning sign.
3. Check the registration (1 minute). Look for a trial ID, such as “NCT” followed by eight digits. ICMJE says any trial that assigns people to a health intervention, including a diet change, should be registered in a public database before the first person enrolls¹². On ClinicalTrials.gov, compare the main outcome the team planned to measure with the result the paper highlights.
4. Match the product (1 minute). Check that the study tested the same extract, dose and form as the product you’re holding, in people like you.
5. Get an independent second opinion (1 minute). Look up the ingredient in an NIH fact sheet or a Cochrane review. The FTC notes that results repeated by independent researchers carry more weight⁶.

Skepticism works best when it applies to everyone

Many people who value natural health learned their skepticism the hard way, from drugs pulled off the market or advice that changed after years of certainty. That skepticism is a strength. It just has to be applied evenly.

If you’d want a drug company’s trial registered in advance, reported in full and repeated by someone else, ask the same of the herb, powder or device you’re considering. Honesty in research doesn’t depend on whether the product came from a lab or a plant.

It also helps to know why so much supplement research is company-funded. Public money exists but is limited. The National Center for Complementary and Integrative Health (NCCIH), the federal research center for this field, had $170.3 million in fiscal year 2024 to cover everything from yoga to herbal medicine¹⁴. In practice, a public grant rarely pays to test one brand’s product, so that work often falls to the company.

That’s why the smart move is to weigh company research, not reject it. A registered, well-designed trial paid for by a company can still be good evidence. A trial that hides its funding, changes its goals midstream or never gets repeated deserves much less trust, no matter who paid for it.

Questions readers ask

The bottom line

Who paid for a study is one of the best single clues to how much to trust it. Company money doesn’t usually produce fake data. It shapes which questions get asked, which results see daylight and how findings are framed, and the best evidence shows that tilt is real.

The fix is to spend five minutes finding the funding, the registration and an independent second opinion, and to hold supplement and wellness research to the same standard you would hold a drug company.

Related reading

• How commissions shape the supplement lists you read online
• Why supplement labels say ‘supports’ and never say ‘cures’
• Third-party tested says what’s in the bottle, not that it works
• Three questions to ask before you pay for a supplement
• Most health products aren’t scams, but many just haven’t been proven

Sources

1. Kearns CE, Schmidt LA, Glantz SA. “Sugar Industry and Coronary Heart Disease Research: A Historical Analysis of Internal Industry Documents.” JAMA Internal Medicine, 2016 (abstract via University of California eScholarship). pubmed.ncbi.nlm.nih.gov
2. Bailey M. “Sugar industry secretly paid for favorable Harvard research.” STAT, republished by PBS NewsHour, 2016. pbs.org
3. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. “Industry sponsorship and research outcome.” Cochrane Database of Systematic Reviews, 2017. cochrane.org
4. Lesser LI, Ebbeling CB, Goozner M, Wypij D, Ludwig DS. “Relationship between funding source and conclusion among nutrition-related scientific articles.” PLoS Medicine, 2007. journals.plos.org
5. Choi C. “AP Exclusive: How candy makers shape nutrition science.” Associated Press (via The Spokesman-Review), 2016. spokesman.com
6. Federal Trade Commission. “Health Products Compliance Guidance.” FTC, 2022. ftc.gov
7. Federal Trade Commission and People of the State of New York. “Complaint, FTC v. Quincy Bioscience Holding Co.” U.S. District Court, Southern District of New York, 2017. ftc.gov
8. New York State Attorney General. “Attorney General James Wins Trial Against Quincy Bioscience for Deceptive and Fraudulent Marketing.” 2024. ag.ny.gov
9. U.S. District Court, Southern District of New York. “Order, FTC and People of the State of New York v. Quincy Bioscience Holding Co.” 2024. ftc.gov
10. U.S. Court of Appeals for the District of Columbia Circuit. “POM Wonderful, LLC v. Federal Trade Commission.” 2015. ftc.gov
11. International Committee of Medical Journal Editors. “Author Responsibilities: Disclosure of Financial and Non-Financial Relationships and Activities, and Conflicts of Interest.” ICMJE, accessed 2026. icmje.org
12. International Committee of Medical Journal Editors. “Clinical Trial Registration.” ICMJE, accessed 2026. icmje.org
13. NIH Office of Dietary Supplements. “Ashwagandha: Fact Sheet for Health Professionals.” National Institutes of Health, 2025. ods.od.nih.gov
14. National Center for Complementary and Integrative Health. “NCCIH Funding: Appropriations History.” National Institutes of Health, accessed 2026. nccih.nih.gov
15. Make America Healthy Again Commission. “Make Our Children Healthy Again: Assessment.” The White House, 2025. whitehouse.gov